32 results about "Dyclonine" patented technology

The invention discloses medical lubricant. The medial lubricant comprises the following components in percentage by weight: 0.02%-0.8% of organic silicon antifoaming agent, 0.2%-3% of dyclocaine hydrochloride, 0.1%-25% of glycerol, 0.1%-10% of xanthan gum and the balance of water. The medical lubricant can be used for realizing good lubricity, a good antifoaming effect and good water solubility; and moreover, the medical lubricant has the effects of a quick surface anesthetic effect and the like.

The invention relates to a mosquito-repelling and itching-relieving cream and discloses a mosquito-repelling and itching-relieving cream which is prepared from natural herbaceous plant extracts, antistine hydrochloride and dyclonine hydrochloride and has the effects of repelling mosquitos and relieving itching. The prescription of the mosquito-repelling and itching-relieving cream comprises the following main ingredients: a combination of any medicines, such as 1-25 percent of antistine hydrochloride, 0.2-15 percent of dyclonine hydrochloride and 6-8 percent of menthol, 3-5 percent of eucalyptus oil, as well as 3-5 percent of camphor and 0.2-0.6 percent of clove basil oil, and 60-80 percent of matrix. The matrix consists of the following components: 10 percent of anhydrous lanolin, 60 percent of albolene and 30 percent of cera alba. The mosquito-repelling and itching-relieving cream is an external preparation prepared from the pure natural herbaceous plant extracts, the antistine hydrochloride and the dyclonine hydrochloride, has the functions of repelling mosquitos and relieving items, refreshing spirit and restoring consciousness and protecting the skin from mosquito bite, has no any toxic and side effects to the body and is safe and reliable to use.

The invention discloses a skin bacteriostatic agent, and simultaneously discloses a preparation method of the skin bacteriostatic agent. Per L of the skin bacteriostatic agent is prepared from the following raw materials: 15-20g of moxa leaves, 1-3g of cordyceps sinensis, 3-6g of red flower, 3-6g of radix clematidis, 3-6g of broom cypress fruit, 5-10g of common cnidium fruit, 2-6g of radix sophorae flavescentis, 3-8g of angelica sinensis, 100ml of propylene glycol, 6-10g of 1-n-Dodecylazacycloneptan-2-ketone, 60g of salicylic acid, 30-50g of dyclonine, 1-5g of phenol, and the balance of 75% ethanol water solution. The skin bacteriostatic agent provided by the invention has obvious curative effect, can be used for treating various skin diseases, and has the advantages of wide use range, short treatment course, instant effect, and no toxic and side effect; and the disease can not relapse after being treated.

The invention belongs to the technical field of pharmaceutic preparation, and particularly relates to a thermo-sensitive type dyclonine hydrochloride gel. The gel is prepared from, by weight, 1%-5% of dyclonine hydrochloride, 1%-10% of thermo-sensitive gel substrate, 5%-10% of viscosity modifier, 0.1%-1% of pH modifier, 0.01%-0.1% of preservative, 0.1%-5% of flavoring agent, 2%-8% of medical defoamer and the balance water. The thermo-sensitive type dyclonine hydrochloride gel is a partial anaesthetic, and is used for laryngeal anesthesia and lubrication during upper gastrointestinal endoscopy; at room temperature, the preparation is in a liquid state, and when temperature rises to animal heat, the preparation can become gel in a cavity or a affected part; under the condition of equivalent dose volume, residence time and cover area ratio are increased drastically; the thermo-sensitive type dyclonine hydrochloride gel has the advantages of being strong in anesthesia, fast in efficacy exertion, good in bubble removing effect, appropriate in mouthfeel and the like, improves the compliance of patients, and is worth clinical application and popularization.

The invention discloses a novel method for synthesizing dyclonine hydrochloride, which uses phenol as a starting material and produces the dyclonine hydrochloride by etherification, acetylation and condensation reaction. The method has the advantages of readily-available raw materials, mild reaction conditions, convenient operation, high yield, good product quality and low cost.

The invention discloses a medicine composition and gel for oral mucosa inflammatory pain and bacteriostasis and a preparation method. Bufalin, dyclonine, chitosan quaternary ammonium salt and epsilon-polylysine are used as the medicine composition to treat symptoms of oral ulcer and mucosa inflammatory pain, the medicine composition is a compound preparation according to the mechanism of pain on the surface of oral ulcer and pain causing base of inhibiting multiple microorganisms on the surface of the ulcer, the bufalin and the dyclonine are combined to quickly block pain conduction of exposednerve endings for a long time, food addition of non-western medicine antibiotics and combination of chitosan quaternary ammonium salt and epsilon-polylysine are adopted to effectively kill multiple pathogenic microorganisms on the surface of the ulcer, inflammatory irritation is further reduced, and the healing function of the wound ulcer is promoted.

The invention provides a zinc oil preparation for treating burn and scald and preparation process thereof, wherein the preparation comprises (by weight proportion) schisandra fruit 4-6 parts, rheum officinale 4-6 parts, notoginseng 2-3 parts, licorice root 4-6 parts, zinc oxide 10 parts, dyclonine 1 part, and ground substance 75-68 parts.

The present invention discloses an oral preparation of dyclonine hydrochloride for the endoscope examination in upper gastrointestinal tract, which has the effects of anaesthetization and lubrication, and especially an oral preparation comprising dyclonine hydrochloride that has the advantages of avoiding the foam in the body cavity, preventing vomit, and offering a clear view. The preparation of the present invention comprises, as main ingredients, 0.2%-3% weight percent of dyclonine hydrochloride, 1%-12% weight percent of polyvinyl alcohol, 1%-10% volume percent of glycerin, 1%-10% volume percent of a defoaming agent, and a balance of a pharmaceutically acceptable adjuvant. The viscosity of the preparation is in a range of 30 to 300 mpa·s and the pH value is in a range of 2.0 to 8.0.

The invention discloses a dental medicinal membrane. The dental medicinal membrane comprises the following components by weight: 3-8g of clotrimazole, 3-8g of dyclonine, 1-3g of metronidazole, 0.3-0.6g of dexamethasone, 10-18g of CMC-Na (sodium carboxymethylcellulose), 40-60g of sodium alginate, 12-18g of tragacanth, 100-150g of ethanol and 1,000-1,500g of purified water. The invention also provides preparation of the dental medicinal membrane, which comprises the following steps: (1) soaking the sodium alginate with ethanol, and grinding in a mortar for later use; (2) naturally peptizing the tragacanth and CMC-Na in the purified water; (3) dissolving the clotrimazole and metronidazole in ethanol, and slowly adding the solution into the mortar in the step (1); dissolving the dexamethasone and metronidazole in the purified water, mixing with the solution in the step (2), slowly adding the mixture into the mortar in the step (1), and constantly grinding to obtain a colloidal liquid; and (4) preparing a membrane from the colloidal liquid, drying and subpackaging. The dental medicinal membrane is low in cost, simple in preparation method and remarkable in treatment effect, and has the effects of inhibiting bacteria and diminishing inflammation; and the dental medicinal membrane is an external application, and is applied to an affected part.

The invention discloses a drug composition, and a preparation method and application thereof, and relates to the field of veterinary drugs. The drug composition comprises a solvent, wherein the solvent is prepared from the following components: 0.02 to 0.2 g / L of dyclonine hydrochloride, 0.05 to 0.2 g / L of terbinafine hydrochloride, and 0.01 to 0.1 g / L of matrine, and the solvent is an aqueous solution of glycerol. When used for treating auditory meatus inflammation of dogs and cats, the drug composition has the advantages of high efficacy, short treatment period and small damage. Furthermore,the invention relates to the preparation method of the drug composition and application of the drug composition in preparation of a drug for treating the auditory meatus inflammation of the dogs andcats.

The invention discloses a process for synthesizing dyclonine hydrochloride. The process comprises the following steps: by taking phenol as a start raw material, firstly, synthesizing phenate butyl with n-butyl bromide; secondly, under the catalysis action of chloride, reacting the phenate butyl with 3-chloropropionyl chloride so as to obtain 3-chlorine-4'-butoxy propiophenone; and further reacting 3-chlorine-4'-butoxy propiophenone with piperidine hydrochloride under the action of triethylamine, thereby obtaining the dyclonine hydrochloride. As an organic solvent is adopted as a solvent, the process is short in reaction time, low in temperature, small in impurity and high in yield, meanwhile the process is simple, no distillation is needed, high-purity phenate butyl is prepared directly, no toxic acetic anhydride is used, and industrial large-scale production is facilitated.

The invention relates to a new application and a use method of dyclonine hydrochloride mucilage, in particular to a new application of dyclonine hydrochloride mucilage in full urethra ultrasonic examination. According to the novel application and the using method of the dyclonine hydrochloride mucilage, the dyclonine hydrochloride mucilage filled urethra ultrasonic examination can provide urethrostenosis information in detail and make correct estimation on the scar tissue range, and the dyclonine hydrochloride mucilage is high in viscosity, can be used for surface anesthesia, improves the examination comfort of a patient, and has a good application prospect. The clinical value is positive. Along with the development of an ultrasonic technology, the hardness of urethral mucosa can be evaluated by utilizing elastic ultrasound, so that the real situation of urethral stricture can be more accurately judged.

The invention discloses a tooth whitening gel containing an anti-allergy agent, the tooth whitening gel comprises solvent water and a pH regulator, and further comprises 1%-50% of an oxidizing agent, 0.1%-10% of a thickening agent and 0.1%-40% of cyclodextrin included anti-allergy agent particles, and the anti-allergy agent is selected from one or more of benzocaine, lidocaine, articaine, dyclonine, tetracaine, ropivacaine and eticaine. The invention also discloses a preparation method of the tooth whitening gel containing the anti-allergic agent. According to the invention, the anti-allergy agent is added into the tooth whitening agent and is clathrated by cyclodextrin, so that the anti-allergy agent is prevented from being oxidized by an oxidizing agent, and the tooth whitening agent has the effect of preventing tooth sensitivity or pain. In the using process, saliva secreted by the oral cavity of a user can decompose cyclodextrin and release the anti-allergy agent in the saliva, the anti-allergy agent is combined with a lipid layer of an oral mucosa at the gingival position, the local anesthesia and analgesia effects are achieved, particularly, stimulation of a high-concentration oxidizing agent to the oral cavity and teeth can be obviously improved, and tooth pain and other discomforts of the user are relieved.

The application discloses a method for detecting the content of dyclonine hydrochloride mucilage or related substances through a high performance liquid chromatography. According to the method, when the content of the dyclonine hydrochloride mucilage is detected, a linear correlation coefficient R2 between the concentration and a peak area in a concentration range equivalent to 10-200% of the concentration of a test sample is greater than 0.9990, the repeatability is good, the quantification limit of the dyclonine hydrochloride is 0.0510 microgram / ml, the average recovery rate is 98-101%, andthe RSD is less than 2.0%. During detection of related impurities, the separation degree between the impurity I and the dyclonine hydrochloride peak is 29.6, the quantitative limit concentration of the impurity I is 1.734 microgram / ml; the linear equation of the impurity I is as follows: A=2*10<7> C-220161, the correlation coefficient is 0.9993, the peak area RSD of the impurity I is 0.6%, the average recovery rate is 97.9%, the RSD is 3.5%, and the detection limit is 0.0041 microgram / ml.

The invention discloses a novel nonirritant quick hemostasis film. The novel nonirritant quick hemostasis film is prepared from 500,000 units of gentamicin, 0.5-2g of polyvinyl alcohol, 10-15g of borneol, 0.5g of tranexamic acid, 0.2-1ml of glycerin, 0.05-0.2g of cortisone, 0.1-1g of dyclonine, 2-5g of sorbitol, 4-10g of sodium carboxymethylcellulose and 150-200ml of distilled water. The novel nonirritant quick hemostasis film is scientific in formulation, remarkable in curative effect and convenient to use and has exact bactericidal, pain relieving and bleeding stopping effects on traumatic bleeding, and pains of patients can be alleviated while pain time is shortened.

The invention relates to the field of pastes, aims to solve the problem of high requirements on adhesion and air permeability of an adhesive layer when the adhesive layer of a plaster is coated on ointment, and provides a plaster for treating arthralgia. The plaster comprises a stripping layer, an ointment layer and a backing layer which are sequentially adsorbed, the inner side of the backing layer is divided into a middle part and a periphery; wherein the ointment layer is attached to the middle part, a circle of adhesive ring is arranged on the periphery of the backing layer, the adhesive ring has viscosity and can be attached to the skin, the stripping layer is attached to the adhesive ring and opposite to the backing layer to clamp the adhesive ring and the ointment layer between theadhesive ring and the ointment layer to play a role in protection, and during use, the stripping layer is stripped off, and the ointment layer comprises indometacin, dyclonine hydrochloride and menthol. The adhesive layer is arranged on the periphery of the ointment layer by a circle, the adhesive ring and the ointment layer do not interfere with each other, and the adhesion between the adhesive ring and the ointment layer does not need to be considered; the ointment layer is in direct contact with the skin without passing through the adhesive ring, so that the human body can better absorb theointment layer, and the permeability of effective components of the ointment in the adhesive ring does not need to be considered.

The invention relates to an erection-assisting time-delay essential oil spray with a yohimbine hydrochloride synergistic effect and a preparation method thereof; a glycerol carbonate / propylene glycol / ethanol solvent system is adopted, a transparent easily-sprayed liquid is obtained, and the problem of yohimbine high-dose dissolution troubling the industry for many years is solved. The obtained spray thoroughly avoids a plurality of harms to human bodies caused by the use of chemically synthesized anesthetic such as lidocaine benzocaine and dyclonine in classical time-delay oil, and scientifically avoids sequelae such as long-time hyperemia, edema, indistinct stabbing pain and dilatation illusion caused by biological product top-speed erection aids such as prostaglandin E1 on penis; the effects of assisting erection, delaying time, improving the quality of sexual life and avoiding sequelae are achieved; the spray prepared from a yohimbine hydrochloride / nano-coated essential oil liposome / glycerol carbonate system and an alcohol-water composition has a rapid and exact curative effect, does not have any toxic or side effect, and does not generate any adverse effect even if being used for a long time through a penis local spray transdermal technology.

The invention discloses an oral ulcer membrane patch and a preparation method thereof. The oral ulcer membrane patch comprises metronidazole, polyvinyl alcohol, borneol, sodium alginate, clotrimazole, azithromycin, glycerol, cortisone, dyclonine, ethanol, distilled water and cod-liver oil. The preparation method of the oral ulcer membrane patch includes: adding the polyvinyl alcohol into the distilled water and heating and dissolving in water bath so as to obtain a solution A; adding the cortisone, the clotrimazole, the dyclonine and the borneol into the ethanol respectively, stirring to dissolve and mixing uniformly so as to obtain a solution B; dissolving the metronidazole into the distilled water and adding the azithromycin to dissolve so as to obtain a solution C; mixing the cod-liver oil with the solution A uniformly; adding the glycerol into the sodium alginate with grinding uniformly, adding the solution B, the solution C and a solution D sequentially, standing and removing bubbles; disinfecting and drying glass plates, sterilizing to coat, naturally drying, cutting and packaging so as to obtain oral ulcer membrane patches. The oral ulcer membrane patch is scientific in composition, remarkable in treatment effect and convenient to use, has exact efficacy when being used for treating patients suffering from oral ulcer and body surface ulcer and is capable of relieving patients' pain and shortening suffering time.

The invention discloses medical lubricant. The medial lubricant comprises the following components in percentage by weight: 0.02%-0.8% of organic silicon antifoaming agent, 0.2%-3% of dyclocaine hydrochloride, 0.1%-25% of glycerol, 0.1%-10% of xanthan gum and the balance of water. The medical lubricant can be used for realizing good lubricity, a good antifoaming effect and good water solubility; and moreover, the medical lubricant has the effects of a quick surface anesthetic effect and the like.

The invention discloses a compound rhizoma coptidis medicine and application thereof. The compound rhizoma coptidis medicine comprises 20% of main medicine and 80% of bases, wherein the main medicine comprises 14-16% of berberine powder, 3-5% of erythromycin powder, 26-29% of metronidazole powder, 15-18% of cortex phellodendri powder, 17-19% of radix scutellariae powder, 5-7% of borneol, 2-4% of dyclonine powder, 10-13% of lidocaine powder and 0.3-0.5% of ethylparaben; an ointment base comprises 8-10 parts of vaseline, 6-9 parts of lanolin, 1-2 parts of beeswax, 2-4 parts of yellow wax; and a suppository base is mixed fatty acid glyceride. The prepared compound rhizoma coptidis medicine has the effects of anti-inflammation, anti-exudation and pain relief; the prepared suppository has fast absorption for rectal administration of acute and chronic anal sinusitis, proctitis, anorectal neuralgia and rectal inflammatory lesions; and the suppository is slowly dissolved for 24 hours, directly acts on local lesions, has significant treatment effect and strong drug permeability, can directly reach the lesions, and has wide application and popularization values.

The invention discloses a brand new synthesis method of dyclonine hydrochloride. According to the method, p-bromoacetophenone is taken as a starting material, and dyclonine hydrochloride is produced through Mannich reaction and C-O cross-linking reaction. Compared with the prior art, the method has the advantages of easily available starting materials, controllable reaction temperature, higher purity, shortened time, increased yield and the like, avoids the use of high-toxicity reagents such as acetyl chloride, 3-chloropropionyl chloride and the like, and is more beneficial to drug safety and industrial mass production.

The invention provides compound lidocaine nano-liposome gel and a preparation method thereof. The nano-liposome gel is prepared from the following raw materials: lidocaine hydrochloride, tetracaine hydrochloride, tetracaine base, lidocaine base, dyclonine hydrochloride, procaine hydrochloride, soyabean lecithin, cholesterol, xanthan gum, carbomer and sodium carboxymethyl cellulose. The preparationmethod of the nano-liposome gel comprises the following steps: S1, preparing raw materials; s2, mixing soyabean lecithin and cholesterol to obtain a mixture A; s3, dissolving carbomer to obtain a mixture B; and S4, adding lidocaine hydrochloride, tetracaine hydrochloride, dyclonine hydrochloride, procaine hydrochloride and the mixture B into the mixture A, performing stirring, adding tetracaine alkali and lidocaine alkali, performing cooling, adding xanthan gum and sodium carboxymethyl cellulose, performing stirring, and performing homogenizing to obtain the compound lidocaine nano-liposome gel. The nano-liposome gel provided by the invention is good in stability in a normal-temperature state and a low-temperature state.

The invention relates to the field of medical supplies and in particular relates to a compound indometacin and dyclonine paste with a waterproof performance and a preparation method of the compound indometacin and dyclonine paste. The compound indometacin and dyclonine paste sequentially includes a waterproof layer, a base cloth layer and a plaster layer, wherein the waterproof layer includes a first waterproof layer and a second waterproof layer, two sides of the base cloth layer are distributed with the first waterproof layer and the second waterproof layer, the second waterproof layer is located between the base cloth layer and the plaster layer, the waterproof layer is a superhydrophobic surface layer, the plaster layer is a traditional Chinese medicine coating layer, and the base cloth layer is a non-woven fabric. Calculated by 100%, the paste includes the components in parts by mass: 2-3 parts of indometacin, 0.1-0.3 part of dyclonine hydrochloride, 7-9 parts of camphor, 3-5 parts of menthol, 29-31 parts of zinc oxide, 22-24 parts of rosin, 3-5 parts of wool fat, 3-5 parts of dimethyl sulfoxide and the balance of rubber. The compound indometacin and dyclonine paste is relatively strong in surface hydrophobicity, not easily attached by dirty marks and relatively strong in air pollution prevention capability.

The present invention relates to methods and compositions for treating tumors. On one hand, the invention relates to an injection which comprises 0.001%-0.2% of aluminum sulfate in terms of anhydrous substances and water for injection. The injection can also contain a local anesthetic, such as the local anesthetic selected from the group consisting of lidocaine, procaine, chloroprocaine, tetracaine, cocaine, dibucaine, prilocaine, mepivacaine, bupivacaine, etidocaine, mesocainum, ropivacaine, pirocaine or dyclonine, preferably lidocaine such as lidocaine hydrochloride. The injection can also comprise the following coloring agents of methylene blue, indigo blue, brilliant blue, patent blue V, gentian violet, copper sulfate, chlorophyll, sodium iron chlorophyllin, copper chlorophyllin, copper chlorophyllin complex salt, sodium copper chlorophyllin and fast green, preferably methylene blue. The invention also relates to application of the injection in preparation of medicines for treating tumors. The injection provided by the invention shows an excellent effect of inhibiting tumor growth.

The invention discloses a novel method for synthesizing dyclonine hydrochloride, which uses phenol as a starting material and produces the dyclonine hydrochloride by etherification, acetylation and condensation reaction. The method has the advantages of readily-available raw materials, mild reaction conditions, convenient operation, high yield, good product quality and low cost.

The invention discloses a combination drug and application thereof. The combination drug is prepared from 20% of a main drug and 80% of a matrix, wherein the main drug is prepared from 24-26% of dragon bones, 3-5% of bulbus fritilariae, 3-5% of Chinese gall, 12-15% of talcum powder, 6-8% of sanguisorba officinalis, 4-6% of radix lithospermi, 3-5% of pseudo-ginseng, 3-5% of bletilla striata, 12-15%of borax, 4-6% of dyclonine, 9-12% of lidocaine, 0.4-0.7% of nipagin, and 4-6% of borneol; and the ointment matrix is prepared from 8-10 parts of Vaseline, 6-9 parts of lanolin, 1-2 parts of beewax and 2-4 parts of yellow wax. A prepared combination drug suppository has effects on lesions in all stages of internal hemorrhoid bleeding and internal hemorrhoid prolapse, absorption is fast through rectal administration, the suppository slowly dissolves for 24 hours to directly act on local lesions, and the treatment effect is remarkable; the effect is the best through anal administration, and internal hemorrhoids are basically healed after 2-3 courses of treatment; and the drug is high in permeability and can directly reach lesions, meanwhile, a preparation method is simple, operation is easy, and wide application and popularization value is achieved.